Windtree Therapeutics Registers 751.8M Shares for Resale, Seeks $50M via ELOC

TL;DR

**WINTW is desperately diluting shareholders to stay afloat, with a massive share registration and ELOC, making it a high-risk bet on a turnaround that's far from guaranteed.**

AI Summary

WINDTREE THERAPEUTICS INC /DE/ (WINTW) filed an S-1 on October 24, 2025, to register the potential resale of up to 751,872,888 shares of common stock by selling stockholders, primarily Seven Knots, LLC and Keystone Capital Partners, LLC. The company will not receive proceeds from these resales, but may receive up to $50 million from sales of Purchase Shares to Seven Knots under an Equity Line of Credit (ELOC) established on July 23, 2025. WINTW reported an accumulated deficit of $861.3 million as of June 30, 2025, and operating losses of $26.1 million and $20.6 million for the years ended December 31, 2024 and 2023, respectively. Cash and cash equivalents stood at $301 thousand with current liabilities of $15.7 million as of June 30, 2025. The company launched a new corporate strategy in January 2025 to become a revenue-generating biotech through acquisitions of small companies with FDA-approved products, and became a manufacturing sourcing agent for Evofem Biosciences' Phexxi in March 2025. A $10 million Commitment Note was issued to Seven Knots as consideration for the ELOC, maturing on April 23, 2026, bearing 5% interest. Additionally, $1.6 million in senior convertible promissory notes due 2026 were issued to two institutional investors on October 9, 2025.

Why It Matters

This S-1 filing signals Windtree Therapeutics' urgent need for capital, highlighted by its $861.3 million accumulated deficit and only $301 thousand in cash as of June 30, 2025. The substantial dilution potential from the 751.8 million shares registered for resale, coupled with the $50 million ELOC, could significantly impact existing investors, especially given the current share price of $0.10. For employees and customers, the success of the new corporate strategy to acquire revenue-generating FDA-approved products is critical for long-term stability. In a competitive biotech landscape, WINTW's ability to execute this strategy and secure non-dilutive funding will determine its viability against better-capitalized peers.

Risk Assessment

Risk Level: high — The company explicitly states, "Investing in our common stock involves a high degree of risk." This is evidenced by an accumulated deficit of $861.3 million as of June 30, 2025, and cash and cash equivalents of only $301 thousand against current liabilities of $15.7 million. The registration of up to 751,872,888 shares for resale, representing a significant portion of the company's market capitalization at a $0.10 share price, indicates substantial potential dilution for existing shareholders.

Analyst Insight

Investors should exercise extreme caution and consider avoiding WINTW shares given the high risk of dilution and the company's precarious financial position. Those considering an investment should wait for clear evidence of successful execution of the new corporate strategy and a significant improvement in financial health, including sustained revenue generation and reduced operating losses.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

$301K

revenue Growth

Not Disclosed

Key Numbers

• $751.8M — Maximum shares registered for resale (Represents potential significant dilution for existing shareholders.)
• $50M — Maximum proceeds from ELOC (Potential capital infusion for the company from Seven Knots.)
• $861.3M — Accumulated deficit as of June 30, 2025 (Indicates substantial historical losses and financial instability.)
• $26.1M — Operating loss for 2024 (Reflects ongoing operational cash burn.)
• $20.6M — Operating loss for 2023 (Shows consistent operational losses year-over-year.)
• $301K — Cash and cash equivalents as of June 30, 2025 (Extremely low cash reserves relative to liabilities and operational needs.)
• $15.7M — Current liabilities as of June 30, 2025 (Significantly exceeds current cash, indicating liquidity challenges.)
• $0.10 — Closing sale price per share on October 22, 2025 (Low share price exacerbates dilution impact of equity financing.)
• $10M — Commitment Note principal amount (Issued to Seven Knots as consideration for the ELOC, bearing 5% interest.)
• $1.6M — Aggregate principal of Subject Notes (Issued to institutional investors on October 9, 2025, convertible into common stock.)

Key Players & Entities

• WINDTREE THERAPEUTICS INC /DE/ (company) — Registrant and issuer of securities
• Seven Knots, LLC (company) — Primary selling stockholder and counterparty to the ELOC Purchase Agreement
• Keystone Capital Partners, LLC (company) — Selling stockholder of Subject Note Shares
• Evofem Biosciences, Inc. (company) — Partner for whom Windtree became a manufacturing sourcing agent for Phexxi
• Zhoake (Hong Kong) Ophthalmology Pharmaceutical Limited (company) — Manufacturing partner for Phexxi
• Varian Biopharmaceuticals, Inc. (company) — Company from which Windtree purchased oncology assets
• Jed Latkin (person) — President and Chief Executive Officer of Windtree Therapeutics, Inc.
• Eric Curtis (person) — Senior Vice President and Chief Operating Officer of Windtree Therapeutics, Inc.
• Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing
• Goodwin Procter LLP (company) — Legal counsel for Windtree Therapeutics, Inc.

FAQ

Risk Factors

• Substantial Accumulated Deficit and Operating Losses [high — financial]: The company has a significant accumulated deficit of $861.3 million as of June 30, 2025, and has incurred operating losses of $26.1 million in 2024 and $20.6 million in 2023. This indicates a history of unprofitability and a substantial need for capital to sustain operations.
• Severe Liquidity Constraints [high — financial]: As of June 30, 2025, Windtree Therapeutics had only $301 thousand in cash and cash equivalents, while facing current liabilities of $15.7 million. This severe mismatch highlights immediate liquidity challenges and a high dependence on external financing.
• Reliance on Equity Line of Credit (ELOC) [high — financial]: The company's ability to continue operations is heavily reliant on the $50 million ELOC with Seven Knots. The S-1 filing is to register shares for resale, which could be sold by Seven Knots, and the company may draw on this ELOC, potentially leading to significant dilution.
• Dilution from Share Resales and ELOC [high — financial]: The registration of up to 751,872,888 shares for resale by existing stockholders, primarily Seven Knots and Keystone Capital Partners, poses a substantial risk of dilution. Coupled with potential draws from the ELOC, this could significantly decrease the value of existing shares.
• Convertible Debt Obligations [medium — financial]: The company has issued $1.6 million in senior convertible promissory notes due 2026 to institutional investors. These notes are convertible into common stock, presenting another potential source of dilution for existing shareholders.
• New Corporate Strategy and Execution Risk [medium — operational]: Windtree Therapeutics launched a new strategy in January 2025 to become a revenue-generating biotech through acquisitions. The success of this strategy, including integrating acquired companies and products, carries inherent execution risks.
• Dependence on Manufacturing Sourcing Agreement [medium — operational]: The company became a manufacturing sourcing agent for Evofem Biosciences' Phexxi in March 2025. The revenue and success of this venture are dependent on the performance and contractual terms with Evofem.
• Commitment Note Obligation [medium — financial]: A $10 million Commitment Note was issued to Seven Knots as consideration for the ELOC, maturing in April 2026 with 5% interest. This represents a near-term debt obligation that needs to be managed.

Industry Context

Windtree Therapeutics operates in the highly competitive and capital-intensive biotechnology sector. The industry is characterized by long development cycles, high failure rates, and significant regulatory hurdles. Companies often rely on external financing, including equity lines and debt, to fund research and development. The trend towards acquiring smaller companies with approved products, as Windtree is pursuing, reflects a strategy to accelerate revenue generation and de-risk the business model in a challenging market.

Regulatory Implications

As a biotechnology company, Windtree is subject to stringent regulations from bodies like the FDA. The S-1 filing itself is a regulatory requirement for public offerings and resales. The company's new strategy involving acquisitions of companies with FDA-approved products means it will need to navigate ongoing compliance and reporting requirements associated with those products and their manufacturing processes.

What Investors Should Do

1. Monitor ELOC Utilization and Dilution
2. Assess Viability of New Corporate Strategy
3. Analyze Cash Burn Rate and Liquidity
4. Evaluate Impact of Share Resales
5. Scrutinize Performance of Sourcing Agent Role

Key Dates

• 2025-10-24: S-1 Filing — Registers up to 751,872,888 shares for resale by selling stockholders, indicating potential significant dilution and a need for capital.
• 2025-07-23: Equity Line of Credit (ELOC) Established — Provided by Seven Knots, allowing the company to potentially raise up to $50 million, crucial for its survival given low cash reserves.
• 2025-03-01: Became Manufacturing Sourcing Agent for Evofem Biosciences' Phexxi — Marks a step towards the new strategy of becoming a revenue-generating biotech, diversifying revenue streams.
• 2025-01-01: Launched New Corporate Strategy — Shift towards acquiring small companies with FDA-approved products, aiming for revenue generation and a new business model.
• 2026-04-23: Commitment Note Maturity Date — The $10 million note issued to Seven Knots matures, requiring repayment or refinancing.
• 2025-10-09: Issuance of Senior Convertible Promissory Notes — Raised $1.6 million from institutional investors, adding convertible debt that could lead to future dilution.

Glossary

S-1 Filing

A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. It provides detailed information about the company's business, financial condition, and the securities being offered. (This filing details the potential resale of a large number of shares and the company's financial situation, directly impacting investors.)

Equity Line of Credit (ELOC)

An agreement where a company can sell shares to an investor at a fluctuating price over a period, up to a certain amount. It provides flexible access to capital. (Windtree Therapeutics has a $50 million ELOC with Seven Knots, which is a critical source of potential funding but also carries dilution risk.)

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net profits. It represents the extent to which a company has lost money over its history. (Windtree's $861.3 million accumulated deficit highlights its long-term unprofitability and significant financial challenges.)

Selling Stockholders

Existing shareholders who are registering their shares with the SEC for resale to the public. The company does not receive proceeds from these sales. (The S-1 filing is primarily for the resale of shares by major stockholders like Seven Knots and Keystone Capital Partners, indicating potential large sell-offs.)

Commitment Note

A promissory note representing a commitment to pay a specified amount of money by a certain date, often used in financing agreements. (Windtree issued a $10 million Commitment Note to Seven Knots as part of the ELOC agreement, representing a debt obligation.)

Senior Convertible Promissory Notes

Debt instruments that pay interest and can be converted into a predetermined number of the issuer's common stock shares. They are 'senior' meaning they have a higher claim on assets in case of bankruptcy than subordinated debt. (Windtree issued $1.6 million of these notes, which represent potential future dilution upon conversion.)

Manufacturing Sourcing Agent

A company that acts as an intermediary to find and manage manufacturers for a product, often handling procurement, quality control, and logistics. (Windtree's role as a sourcing agent for Evofem's Phexxi is part of its new strategy to generate revenue.)

Dilution

The reduction in the ownership percentage of a stock that occurs when a company issues additional shares. This can decrease the earnings per share and the voting power of existing shareholders. (The large number of shares being registered for resale and the potential issuance of new shares from convertible notes pose a significant dilution risk for current WINTW shareholders.)

Year-Over-Year Comparison

This S-1 filing represents a significant shift from previous filings, primarily due to the company's new strategic direction and its precarious financial position. While specific comparative financial data from a prior S-1 isn't detailed here, the current filing highlights a substantial accumulated deficit ($861.3M as of June 30, 2025) and critically low cash reserves ($301K). The introduction of a large Equity Line of Credit and the registration of a massive number of shares for resale indicate a heightened need for capital and a potential for significant dilution, risks that may have been less pronounced or structured differently in prior periods.

Key Financial Figures

• $0.001 — 2,771 shares of common stock, par value $0.001 per share ("common stock"), issuable by
• $50 million — on stock. However, we may receive up to $50 million from sales of Purchase Shares to Seven
• $0.10 — mon stock on The OTCID Basic Market was $0.10 per share. We are a "smaller reporting
• $861.3 million — 2025, we had an accumulated deficit of $861.3 million. For the years ended December 31, 2024
• $26.1 million — 24 and 2023, we had operating losses of $26.1 million and $20.6 million, respectively. As of
• $20.6 m — d operating losses of $26.1 million and $20.6 million, respectively. As of December 31,
• $846.6 million — 2024, we had an accumulated deficit of $846.6 million. To date, we have financed our operatio
• $301 thousand — 25, we had cash and cash equivalents of $301 thousand and current liabilities of $15.7 millio
• $15.7 million — 301 thousand and current liabilities of $15.7 million. To date, we have financed operations p
• $500 m — tal maximum aggregate purchase price of $500 million, of which $50 million is register
• $0.50 — ommon stock is equal to or greater than $0.50 (the "VWAP Purchase Date"), we may dire
• $10,000,000 — nt Note to Seven Knots in the amount of $10,000,000. The Commitment Note matures on April 2
• $500 million — Meeting of Stockholders to issue up to $500 million of ELOC Shares under the ELOC Purchase
• $1,600,000 — tes in an aggregate principal amount of $1,600,000, which are convertible, at the option o
• $1.00 — common stock has been below the minimum $1.00 per share required for continued listin

Filing Documents

• wint20251022_s1.htm (S-1) — 4863KB
• ex_875441.htm (EX-3.3) — 12KB
• ex_875038.htm (EX-5.1) — 18KB
• ex_875897.htm (EX-10.90) — 31KB
• ex_875440.htm (EX-23.1) — 3KB
• ex_875039.htm (EX-FILING FEES) — 25KB
• ex_875038img001.jpg (GRAPHIC) — 2KB
• logolrg.jpg (GRAPHIC) — 56KB
• logosm.jpg (GRAPHIC) — 8KB
• 0001437749-25-031723.txt ( ) — 20861KB
• wint-20250630.xsd (EX-101.SCH) — 153KB
• wint-20250630_cal.xml (EX-101.CAL) — 104KB
• wint-20250630_def.xml (EX-101.DEF) — 1320KB
• wint-20250630_lab.xml (EX-101.LAB) — 692KB
• wint-20250630_pre.xml (EX-101.PRE) — 1358KB
• wint20251022_s1_htm.xml (XML) — 2679KB
• ex_875039_htm.xml (XML) — 5KB

RISK FACTORS

RISK FACTORS 9 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 56 THE COMMITTED EQUITY FINANCING 58

USE OF PROCEEDS

USE OF PROCEEDS 62 DIVIDEND POLICY 63

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 64

BUSINESS

BUSINESS 80 MANAGEMENT 112 EXECUTIVE AND DIRECTOR COMPENSATION 117 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 125 SELLING STOCKHOLDERS 128

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 130

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 131 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 135 PLAN OF DISTRIBUTION 139 LEGAL MATTERS 141 EXPERTS 141 WHERE YOU CAN FIND MORE INFORMATION 142 INDEX TO FINANCIAL STATEMENTS F-1 Table of Contents ABOUT THIS PROSPECTUS The registration statement we filed with the U.S. Securities and Exchange Commission (the "SEC") includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus, the related exhibits filed with the SEC, and the documents incorporated by reference herein before making your investment decision. You should rely only on the information provided in this prospectus and the documents incorporated by reference herein or any amendment or supplement thereto. You should not assume that the information contained in this prospectus or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference herein or therein is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus or any related free writing prospectus is delivered, or securities are sold, on a later date. We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. This prospectus contains or incorporates by reference summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. You should read the entire prospectus, any amendments or supplements, and the information incorporated by reference in this prospectus carefully. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been or will be filed or have been or will be incorporated by reference as exhibits to the registration

View Full Filing

View this S-1 filing on SEC EDGAR